[ad_1]
The Securities and Futures Commission of the Financial Services Commission (FSC) held a regular meeting on April 4 and began the fourth deliberation on the supervision measures of Samsung Bio Logics (Samsung Bio).
The Supreme Court of Korea (FSS) stated that the FSS and Samsung Biotech were present at the same time and held a meeting with the Supreme Court to announce their position.
On April 4, according to the Ministry of Finance, Koo added that he was holding a regular meeting in the afternoon and continued deliberation on Samsung's existing control measures Biotech.
This deliberation is the fourth after the ordinary meeting on the 7th of last month, the ordinary meeting on the 12th and the ordinary meeting on the 21st.
On the morning of this morning, the prosecution dealt with the issue. other agenda. In the afternoon, Samsung Bio Supervision Act is under discussion.
Koo supposed to listen to the opinions of both sides on the measures that were discussed.
The Financial Supervisory Service (FSS) estimates that Samsung Biotech has suddenly changed its subsidiary, Samsung BioEpice, from a subsidiary to a related company.
Although the Financial Supervisory Service (FSS) ruled that it was "misdemeanor" accounting, Samsung Biotech had the opportunity to exercise the option of Purchase (purchase option) of US Bioenergy due to the increase in the business value of its subsidiaries "He said.
Biogen is a multinational pharmaceutical company that co-founded Samsung Bio Epithegy with Samsung Biotech, which has a purchase option to take a 50% -1 stake in the creation of Samsung Biopies.
Indeed, Biogen will call options at the end of last month, and its shareholder ratio will rise to 49.9%. Samsung Biotech's stake in Samsung Bio was 94.6% and Biogen 5.4%.
At this meeting, the Supervisory Board also deliberates on the modification of the newly announced surveillance measure by the FSS.
Koo pleaded with the Financial Supervisory Service (FSS) after the third meeting last month to request some supplementation of the monitoring measures.
This was a request to refine Samsung Biotech's decision to change the judgment of Samsung Bio-Peace Control and the direction of the revision of the financial statements by year.
Indeed, Samsung Biotech must review the entire period from 2012 to 2014, since its creation in 2012 until there is more room for Samsung BioEpice to be counted in as a subsidiary rather than a subsidiary.
An official of the Financial Supervisory Commission stated: "The Financial Supervisory Commission (FSS) reports on the new measures,
However, the new measure must be taken over from Samsung Bioscience's advance notification process, so it was reported that only the FSS was considered impossible.
For Samsung Bio to challenge the new measure in the Supreme Court, it is necessary to receive and prepare a few days' notice to obtain the right to defend it, but the Financial Supervisory Service has set up a new measure until the day before. It is also possible that the final decision will be delayed if the prosecution is upheld.
The Financial Supervisory Commission (FSC) has repeatedly announced that it will close the Supreme Court appeal proceedings in the middle of the month whenever possible.
The Supreme Court intends not to deliberate on the Supervisory Commission, which is an advisory body, with regard to the new measures. The reason is that discussions have already taken place on how to deal with accounting before 2014.
(Seoul-Yonhap News)
Source link
